Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The group will offer free access to omic and clinical data from the project and develop software to help clinicians use the models in patient care.
The partners have planned a three-year pilot and selected three NCI projects to benefit from supercomputers and expertise offered by four DOE labs.
Myriad Genetics, Kinaxo Biotechnologies, Bavarian Research Foundation, European Commission, Decode Genetics, Ontario Institute for Cancer Research
The $3.8 million program will back assay development, screening tools, toxicity, and elucidation of 3D structures in search of HIV treatments
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.